David Hirsch, the Company's Acting CEO and CFO stated, "Our current financial condition coupled with the difficult economic climate has left us with a limited number of options to adequately fund the Company such that we can continue operations. While we remain optimistic that we will find an alternative that will allow us to continue to operate as a going concern, there can be no assurance that we will be able to do so."
About Oragenics
Oragenics, Inc. is a biopharmaceutical company engaged in developing unique proprietary technologies, some of which are being commercialized and sold in the over-the-counter consumer healthcare market. The company also has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, diagnostics, and oral health. The company is located in Progress Corporate Park at 13700 Progress Boulevard in Alachua, Florida, approximately 15 miles from the campus of the University of Florida in Gainesville.
Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company's current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.
SOURCE: Oragenics, Inc.
Oragenics, Inc. David Hirsch, Acting CEO, CFO, +1 386 418 4018 dhirsch@oragenics.com

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index